Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 7Neoplasms 6Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Carcinoid Tumor 5Stomach Neoplasms 4Esophageal Neoplasms 4Acromegaly 4Weight Loss 3Rectal Neoplasms 3Pancreatic Neoplasms 3Diarrhea 3Carcinoma 3Breast Neoplasms 3Vipoma 2Thymoma 2Somatostatinoma 2Pituitary Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Malnutrition 2Intestinal Obstruction 2Insulinoma 2Glucagonoma 2Colonic Neoplasms 2Carcinoma, Islet Cell 2Adenoma, Islet Cell 2Zollinger-Ellison Syndrome 1Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1

Interventions

Trastuzumab 2Octreotide 2Leucovorin 2tipifarnib 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Temozolomide 1Sorafenib 1Salts 1Oxaliplatin 1Melphalan 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Gefitinib 1Fluorouracil 1Floxuridine 1Fentanyl 1Everolimus 1Disulfides 1Capecitabine 1Bevacizumab 1Acetates 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Vipoma × Octreotide × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT01229943 2022-08-04

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
150 enrolled 12 charts

Vipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡